Okyo Pharma announces FDA granted FTD to urcosimod

OKYO Pharma (OKYO) announces that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, to urcosimod for the treatment of neuropathic corneal pain, NCP. Gary Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, expressed his enthusiasm about the FDA’s decision: “We are thrilled with the FDA’s Fast Track designation for urcosimod in the treatment of neuropathic corneal pain. This milestone underscores our commitment to advancing innovative therapies that can make a meaningful difference in patients’ lives. We look forward to working closely with the FDA to bring this promising treatment to patients as quickly as possible.”